Bioject Enters into Three Distribution Agreements

Two in the Pacific Rim and One in the Middle East

TIGARD, Ore.--()--Bioject Medical Technologies Inc. (OTC Pink: BJCT), a developer and manufacturer of needle-free injection therapy systems, today announced that it has entered into three international distribution agreements, two in the Pacific Rim region and one in the Middle East. The agreements call for the sale of the Biojector®2000 gas-powered device, the Bioject® ZetaJet™ spring-powered device and accessories through qualified medical device groups located in Australia, the Republic of the Philippines, and North Africa. The agreements provide for distribution in multiple territories throughout the regions.

“We are pleased to have entered into these agreements, as it expands the use of our needle-free devices throughout the world,” said Mr. Mark Logomasini, Bioject’s President and CEO. “In partnership with our distributors, we are looking forward to developing relationships with new users of Bioject’s needle-free technology.”

Bioject Medical Technologies Inc., based in Tigard, Oregon, USA, is a developer and manufacturer of needle-free injection therapy systems (NFITS). NFITS works by forcing medication at high speed through a tiny orifice held against the skin. This creates a fine stream of high-pressure fluid penetrating the skin and depositing medication in the tissue beneath. Bioject is focused on developing mutually beneficial agreements with leading pharmaceutical, biotechnology, and veterinary companies, as well as research, global health and government organizations.

Readers and potential investors are cautioned that an investment in the Company’s securities involve an EXTREMELY high degree of risk. Such risks include, without limitation, the risk that these distribution agreements will not be successful due to the time required in obtaining government clearances and the risk that the Company may be unable to comply with the extensive government regulations applicable to the business.

Bioject (OTC Pink: BJCT) trades on the OTC Pink tier of the OTC market. Investors can find Real-Time quotes and market information for the Company on www.otcmarkets.com.

For more information about Bioject, visit www.bioject.com.

Contacts

Bioject Medical Technologies Inc.
Mark Logomasini, 503-692-8001 ext. 4121
President and CEO
or
Christine Farrell, 503-692-8001 ext. 4132
Vice President of Finance

Contacts

Bioject Medical Technologies Inc.
Mark Logomasini, 503-692-8001 ext. 4121
President and CEO
or
Christine Farrell, 503-692-8001 ext. 4132
Vice President of Finance